Merck KGaA's Allergopharma opens production facility
The 6,000sqm facility will be operated by Merck’s subsidiary Allergopharma and will focus on the production of treatments for allergy, including allergic asthma and hay fever.
Merck has been constructing the facility since 2013. At the time the firm said the facility would support expansion into new markets including China.
This was reiterated by COO Simon Sturge who said on Thursday that the facility is part of a "global expansion, and will support our growing business in the allergy market place.”